2seventy bio, Inc.: 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from

Related Keywords

Belgium ,Leuven ,Region Flamande ,Heidelberg ,Baden Wüberg ,Germany ,Chicago ,Illinois ,United States ,University Of Texas ,Texas ,Houston ,France ,Afshin Mashadi Hossein ,Yi Lin ,Krina Patel ,Hemophagocytic Lymphohistiocytosis ,Michel Delforge ,Julia Piasecki ,Melissa Alsina ,Bristol Myers Squibb ,Salomon Manier ,Marcs Raab ,Morgan Adams ,Steve Bernstein ,Centre Hospitalier Universitaire De Lille ,Heidelberg University Hospital ,Exchange Commission ,Linkedin ,Twitter ,Moffitt Cancer Center ,European Hematology Association ,Md Anderson Cancer Center ,Nasdaq ,University Of Leuven ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Annual Meeting ,Nicholas Stong ,Cancer Center ,Mayo Clinic ,Profit Share Agreement ,Release Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Igg Secondary Malignancies ,Operate Machinery ,Prescribing Information ,Cautionary Note Regarding Forward Looking ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Gefallene Big Techs ,2seventy ,Nnounces ,Dditional ,Data ,Rom ,Carmma ,Studies ,Abecma ,Idecabtagene ,Icleucel ,Disco ,023 ,